Diabetic Gastroparesis Drug Development- Pipeline Analysis Report

Diabetic Gastroparesis Drug Development- Pipeline Analysis Report

  • May 2018 •
  • Report ID: 5390321 •
  • Format: PDF
With an estimated 3-5 million people in the US suffering from gastroparesis, with young population around 34 years being more susceptible, the Diabetic Gastroparesis presents significant market opportunities of around $5 billion to $6 billion. Metoclopramide is the only FDA approved drug for treatment of the disease and acoordingly, several researchers are focusing on developing new treatment options for the disease. Diabetic Gastroparesis is a GI disorder in which the stomach takes longer periods for emptying the contents.

Around 15 companies and universities are focusing on developing treatment options for Diabetic gastroparesis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Diabetic gastroparesis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Diabetic gastroparesis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Diabetic gastroparesis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.